Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
